Nurix TherapeuticsÂ Inc (NRIX) Financials

$26.26

$0.13 (0.50%)

As on 09-Sep-2026 16:00EDT

Market cap

$2,713 Mln

Revenue (TTM)

$37 Mln

P/E Ratio

--

P/B Ratio

6.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Operating Revenue	36.77	83.98	54.55	76.99	38.63	29.75
Cost of Revenue	97.62	18.86	221.63	189.15	10.81	6.08
Gross Profit	-60.85	65.12	-167.08	-112.16	38.63	29.75
Operating Expenses	300.33	350.79	45.94	42.90	222.49	147.64
Operating Profit (EBIT)	-361.18	-285.67	-213.03	-155.06	-183.87	-117.89
Other Income	--	--	--	--	3.51	0.82
Profit before Tax	-341.62	-263.70	-193.30	-143.95	-180.36	-117.06
Provision for Tax	-0.27	0.76	0.27	13.49	-14.32	0.13
Profit after Tax (Net Income)	-341.35	-264.46	-193.57	-143.95	-166.05	-117.19
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-180.36	-117.19

Liabilities ($ Mln)	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Shareholder's Funds	402.63	538.75	526.99	200.49	303.70	342.30
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	60.89	62.92	46.50	68.15	42.41	68.21
Current Liabilities	72.02	86.47	95.85	86.96	70.66	66.26
Total Liabilities	607.56	688.14	669.34	355.60	416.76	476.77

Assets ($ Mln)	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Non-Current Assets	79.06	81.32	49.96	60.10	98.31	165.65
Current Assets	456.48	606.82	619.39	295.50	318.45	311.12
Total Assets	607.56	688.14	669.34	355.60	416.76	476.77
Total Debt*	58.14	55.73	28.30	30.61	11.96	13.04
Net Current Assets	384.46	520.35	523.53	208.55	247.79	244.86

Cashflow ($ Mln)	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Cash From Operating Activities	--	-249.47	-172.58	-81.37	-159.81	-84.37
Cash Flow from Investing Activities	--	147.85	-257.71	68.30	27.20	-108.25
Cash from Financing Activities	--	238.64	485.67	3.22	117.19	153.88
Net Cash Inflow / Outflow	--	--	--	--	-15.42	-38.73

Financials Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
ROCE (%)	--	-46.00	-49.23	-52.65	-49.49	-36.31
ROE (%)	-72.52	-49.63	-53.22	-57.10	-51.41	-37.05
ROA (%)	-53.56	-38.96	-37.77	-37.27	-37.17	-26.85
EBIT Margin (%)	-929.18	-314.00	-354.36	-186.98	-476.01	-396.26
Net Margin (%)	-928.44	-314.90	-354.85	-186.98	-394.09	-383.33
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Revenue Growth (%)	-58.40	0.54	-0.29	0.99	0.30	0.67
EBIT Growth (%)	-65.46	-36.42	-34.28	21.71	-55.97	-81.41
Net Profit Growth (%)	-64.65	-36.62	-34.47	13.31	-41.68	-171.02
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Price / Earnings	--	--	--	--	--	--
Price / Book Value	6.65	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-3.35	2.19	3.14	1.87	1.72	2.53
Close Price ($)	17.76	17.68	22.11	6.22	12.39	28.82
High Price ($)	22.50	23.00	29.56	13.99	32.18	52.38
Low Price ($)	8.20	8.18	5.95	4.22	7.52	21.53
Market Cap ($ Cr)	2,712.85	--	--	--	--	--

Solvency Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Debt to Equity	--	0.10	0.05	0.15	0.04	0.04
Short term debt to equity ratio	0.01	0.01	0.02	0.04	0.02	0.01
Current Ratio	6.34	7.02	6.46	3.40	4.51	4.70
Quick Ratio	6.34	--	--	--	4.52	4.70
Interest Coverage	--	--	--	--	-12.84	-17.07

Operating Efficiency Ratios	TTM	Nov-25	Nov-24	Nov-23	Nov-22	Nov-21	Nov-20	Nov-19	Nov-18	Nov-17	Nov-16
Debtors to sales (%)	--	--	2.75	1.04	2.85	20.85
Asset Turnover	0.06	0.12	0.11	0.20	0.09	0.07
Receivable days	--	6.52	7.70	4.51	34.53	107.73
Inventory Days	--	--	--	-2.12	-18.59	0.00
Payable days	--	219.83	14.74	11.07	197.93	302.13
Cash Conversion Cycle	--	--	--	-8.69	-181.99	-194.40

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.